On November 7th, the "2025 CACA Integrated Cancer Prevention and Control Sci-Tech Innovation Competition Grand Finals" successfully concluded in Kunming, Yunnan. Hosted by the China Anti-Cancer Association (CACA) and its Industry-Academia-Research Committee, and co-organized by the World Association for Integrated Oncology (WAIO) and the China Academy of Integrated Medicine Development Strategies, the competition was themed "Gathering Wisdom for Integration, Illuminating New Pathways in Cancer Prevention and Control." It attracted hundreds of projects from medical institutions, research institutes, and innovative enterprises across China. After rigorous selection processes, 12 outstanding teams advanced to the finals, engaging in fierce competition centered on innovation across the entire spectrum of cancer prevention and control.

Among the numerous entries, the project titled "Construction of a Multimodal AI Diagnostic Model and Clinical Translation Research Based on the miRNA7 Detection Kit," presented by Dr. Chen Junbing on behalf of the team led by Professor Sun Yunfan from Zhongshan Hospital Affiliated with Fudan University, stood out for its innovation and clinical translation value, earning third place in the clinical category at the finals.

This project's achievements are based on research findings from Zhongshan Hospital Affiliated with Fudan University and utilize miRNA7, the first liver cancer molecular detection kit in China developed in collaboration with Dunwill Medical to receive NMPA approval, which has also obtained a national authorized invention patent. By constructing a multimodal fusion large model, this research provides a powerful tool for holistic tumor cycle management and stratified health management, holding significant clinical application value. The project results demonstrate a complete closed loop from scientific research to clinical application, offering a new pathway to promote innovative development in China's cancer prevention and control field.

Dunwill Medical consistently adheres to a clinical needs-oriented approach, employing an innovative industry-academia-research collaboration model where "medical institutions lead technology R&D, and enterprises ensure production and product quality." This has effectively facilitated the efficient translation of scientific research results into clinical application. This award not only represents high recognition of the project team's innovative capabilities but also further validates the company's comprehensive strength in R&D and clinical translation through its integrated "Medical-Research-Production" full-process closed-loop solution.

Looking ahead, Dunwill Medical will continue to actively implement the "Healthy China 2030" strategy, promote deeper integration of industry, academia, and research, accelerate breakthroughs and model innovation in early cancer screening technologies, and jointly advance the cause of cancer prevention and control towards a more efficient and accessible future.